Original disclosure @ IFC website
Updated in EWS Dec 16, 2022
Disclosed by Bank Nov 22, 2022
Can you contribute information about this project?
Contact the EWS Team
According to the Bank’s website, Knight Therapeutics Inc. is a pan-American (ex-USA) specialty pharmaceutical company headquartered in Montreal, Canada that was founded in 2014 with the objective of acquiring or in-licensing innovative pharmaceutical products. In 2019, Knight acquired a controlling stake in Grupo Biotoscana (“GBT”), a specialty pharmaceutical company with a presence across Latin America. Knight completed the 100% acquisition in August 2020. GBT owns manufacturing facilities for branded generic products in addition to a research and development center, all located in Argentina. With the GBT acquisition, Knight has expanded its operations in Latin America. The company is now directly present in 11 countries and has distributors in Central America and the Caribbean. The proposed IFC investment will be used to partially provide financing in connection with the acquisition of the rights to manufacture, market and sell Exelon® in Canada and Latin America, as well as an exclusive license to use the intellectual property and the Exelon® trademark, from Novartis within the Territory, as well as its commercialization in Canada and Latin America. Exelon® is indicated for the symptomatic treatment of mild to moderately severe dementia in people with Alzheimer’s disease and Parkinson’s disease.
|Private Actor 1||Private Actor 1 Role||Private Actor 1 Sector||Relation||Private Actor 2||Private Actor 2 Role||Private Actor 2 Sector|
|-||-||-||-||Knight Therapeutics Inc.||Client||-|
Contact Person: Arvind Utchanah
Company Name: Knight Therapeutics Inc.
Address: 3400 De Maisonneuve Blvd. W., Suite 1055, Montreal QC. H3Z 3B8, Canada
Telephone Number: +1 514 484 4483 ext. 115
Fax: +1 514 481 4116
ACCESS TO INFORMATION
You can submit a request for information disclosure at: https://disclosures.ifc.org/#/inquiries
If you believe that your request for information from IFC has been unreasonably denied, or that this Policy has been interpreted incorrectly, you can submit a complaint at the link above to IFC's Access to Information Policy Advisor, who reports directly to IFC's Executive Vice President.
ACCOUNTABILITY MECHANISM OF IFC/MIGA
The Compliance Advisor Ombudsman (CAO) is the independent complaint mechanism and fact-finding body for people who believe they are likely to be, or have been, adversely affected by an IFC or MIGA- financed project. If you submit a complaint to the CAO, they may assist you in resolving a dispute with the company and/or investigate to assess whether the IFC is following its own policies and procedures for preventing harm to people or the environment. If you want to submit a complaint electronically, you can email the CAO at CAO@worldbankgroup.org You can learn more about the CAO and how to file a complaint at http://www.cao-ombudsman.org